We are live on ! Find out more
TAK icon

Takeda Pharmaceutical

334 hedge funds and large institutions have $1.25B invested in Takeda Pharmaceutical in 2025 Q3 according to their latest regulatory filings, with 58 funds opening new positions, 136 increasing their positions, 78 reducing their positions, and 42 closing their positions.

New
Increased
Maintained
Reduced
Closed

1,201% more call options, than puts

Call options by funds: $25.3M | Put options by funds: $1.95M

115% more capital inflows, than outflows

Capital inflows: $204M | Capital outflows: $94.9M

74% more repeat investments, than reductions

Existing positions increased: 136 | Existing positions reduced: 78

38% more first-time investments, than exits

New positions opened: 58 | Existing positions closed: 42

4% more funds holding

Funds holding: 321 → 334 (+13)

0.2% more ownership

Funds ownership: 2.49% → 2.7% (+0.2%)

Holders
334
Holders Change
+13
Holders Change %
+4.05%
% of All Funds
4.36%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
58
Increased
136
Reduced
78
Closed
42
Calls
$25.3M
Puts
$1.95M
Net Calls
+$23.4M
Net Calls Change
-$3.02M

TAK Hedge Fund Activity: Q3 2025 in Review

334 of the 7,664 institutional investors tracked by Wall St. Rank reported a position in Takeda Pharmaceutical (TAK) for Q3 2025, worth a combined $1.25B — up 3.6% from $1.2B a quarter earlier.

Buyers outnumbered sellers: 58 funds opened new TAK positions and 42 closed out — a net gain of 16 holders — while 136 added to existing stakes and 78 trimmed.

The largest buyer was Toronto Dominion Bank, opening a new position worth an estimated $44.6M. The largest seller was Adage Capital Partners, exiting entirely with an estimated $39.2M sold.

  • 334 institutional investors held Takeda Pharmaceutical (TAK) as of Q3 2025, up from 321 in Q2 2025.
  • Funds reported $1.25B of Takeda Pharmaceutical stock for Q3 2025, up 3.6% quarter-over-quarter.
  • 58 funds opened new Takeda Pharmaceutical positions in Q3 2025 and 42 closed out, a net change of +16 holders.
  • The largest Takeda Pharmaceutical buyer in Q3 2025 was Toronto Dominion Bank, an estimated $44.6M added.
  • The largest Takeda Pharmaceutical seller in Q3 2025 was Adage Capital Partners, an estimated $39.2M sold.

Based on aggregated 13F filings for Q3 2025.